Order Article Reprints

Hammitt LL, Buchwald UK, McCauley J, Shekar T, Fu W, Cheon K, Sterling T, Tamms G, Banniettis N, Musey L, et al. Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18–49 Years of Age Enrolled at Center for Indigenous Health Sites. Vaccines. 2026; 14(1):3. https://doi.org/10.3390/vaccines14010003

Hammitt, Laura L., Ulrike K. Buchwald, Jennifer McCauley, Tulin Shekar, Wei Fu, Kyeongmi Cheon, Tina Sterling, Gretchen Tamms, Natalie Banniettis, Luwy Musey, and et al. 2026. "Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18–49 Years of Age Enrolled at Center for Indigenous Health Sites" Vaccines 14, no. 1: 3. https://doi.org/10.3390/vaccines14010003

Hammitt, L. L., Buchwald, U. K., McCauley, J., Shekar, T., Fu, W., Cheon, K., Sterling, T., Tamms, G., Banniettis, N., Musey, L., LeBlanc, J. J., Weatherholtz, R., Riley, D. P., Denny, E., Tso, C., Roessler, K., & Santosham, M. (2026). Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18–49 Years of Age Enrolled at Center for Indigenous Health Sites. Vaccines, 14(1), 3. https://doi.org/10.3390/vaccines14010003